Pharmacoeconomic Analysis of CAR-T Cell Therapy in Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemias

Genetically modified Т-lymphocytes with chimeric antigen receptors (CAR-T cells) represent a new treatment strategy in relapsed/refractory B-cell malignant neoplasms. In 2017–2018 two CAR-T cell drugs, tisagenlecleucel and axicabtagene ciloleucel, were approved by the U.S. Food and Drug Administrati...

Descrición completa

Detalles Bibliográficos

Principais autores:	Irina Vladimirovna Gribkova, A. A. Zavyalov
Formato:	Artigo
Idioma:	Russo
Publicado:	Practical Medicine Publishing House 2022-04-01
Series:	Клиническая онкогематология
Assuntos:	b-cell lymphoma acute lymphoblastic leukemia car-t cell therapy chimeric antigen receptor tisagenlecleucel axicabtagene ciloleucel costs review
Acceso en liña:	https://bloodjournal.ru/index.php/coh/article/view/142
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!